Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Spoke,
| Spoke Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME…
| Spoke Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME…
BURLINGAME, Calif.--(Business Wire)-- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of…
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of…
An antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumor effects, an…
(Medical Xpress)—An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-env…
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of…
SOUTH SAN FRANCISCO Calif. Aug. 14 2014 PRNewswire &160;KaloBios Pharmaceuticals Inc. Nasdaq KBIO today announced the…